See more : Winnebago Industries, Inc. (WGO) Income Statement Analysis – Financial Results
Complete financial analysis of ReNeuron Group plc (RNUGF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of ReNeuron Group plc, a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Sandbridge X2 Corp. (SBII-WT) Income Statement Analysis – Financial Results
- MVP Holdings Inc. (MVPT) Income Statement Analysis – Financial Results
- Michman Basad Ltd (MCMN.TA) Income Statement Analysis – Financial Results
- Gujarat Fluorochemicals Limited (FLUOROCHEM.BO) Income Statement Analysis – Financial Results
- Novacyt S.A. (ALNOV.PA) Income Statement Analysis – Financial Results
ReNeuron Group plc (RNUGF)
About ReNeuron Group plc
ReNeuron Group plc researches, develops, and commercializes cell-based therapies in the United Kingdom. The company engages in the development of CTX stem cell therapy candidate for treating stroke disability; and human retinal progenitor cell therapy that is in Phase 2 clinical trial for treating retinitis pigmentosa, a blindness-causing disease. It also develops CTX-derived exosomes that are in the pre-clinical stage, which are Nano-sized packages of information released by CTX cells. In addition, the company licenses ReNcell products. It has a collaboration agreement with University College London to conduct research into the generation of immune cells from induced pluripotent stem cells for anti-cancer cell therapies. The company was founded in 1997 and is headquartered in Pencoed, the United Kingdom.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 530.00K | 403.00K | 257.00K | 6.07M | 49.00K | 43.00K | 46.00K | 29.00K | 30.00K | 22.00K | 17.00K | 40.00K | 29.00K | 31.00K | 93.00K | 27.00K | 49.00K | 9.00K | 3.00K | 1.00K | 19.00K |
| Cost of Revenue | 267.00K | 324.00K | 9.50M | 16.34M | 16.25M | 16.66M | 169.00K | 92.00K | 7.25M | 5.83M | 4.79M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 263.00K | 79.00K | -9.25M | -10.27M | -16.20M | -16.61M | -123.00K | -63.00K | -7.22M | -5.81M | -4.77M | 40.00K | 29.00K | 31.00K | 93.00K | 27.00K | 49.00K | 9.00K | 3.00K | 1.00K | 19.00K |
| Gross Profit Ratio | 49.62% | 19.60% | -3,597.67% | -169.33% | -33,055.10% | -38,637.21% | -267.39% | -217.24% | -24,066.67% | -26,395.45% | -28,052.94% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| Research & Development | 4.46M | 8.07M | 6.00M | 16.34M | 16.26M | 16.66M | 16.65M | 10.27M | 7.25M | 5.83M | 4.79M | 4.87M | 3.76M | 2.08M | 3.18M | 5.17M | 4.42M | 4.33M | 2.40M | 0.00 | 0.00 |
| General & Administrative | 1.13M | 1.13M | 728.00K | 1.91M | 4.75M | 4.62M | 4.14M | 4.02M | 3.69M | 2.82M | 2.32M | 2.06M | 3.07M | 1.91M | 1.58M | 2.06M | 1.86M | 1.61M | 987.00K | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 1.13M | 1.13M | 728.00K | 1.91M | 4.75M | 4.62M | 4.14M | 4.02M | 3.69M | 2.82M | 2.32M | 2.06M | 3.07M | 1.91M | 1.58M | 2.06M | 1.86M | 1.61M | 987.00K | 0.00 | 0.00 |
| Other Expenses | 2.05M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 854.00K | -5.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 7.65M | 11.63M | 12.57M | 20.57M | 19.13M | 20.42M | 19.93M | 13.75M | 10.42M | 7.99M | 7.11M | 6.92M | 6.70M | 3.96M | 4.80M | 6.92M | 6.01M | 5.94M | 3.34M | 3.31M | 4.84M |
| Cost & Expenses | 7.65M | 11.63M | 12.57M | 20.57M | 19.13M | 20.42M | 19.93M | 13.75M | 10.42M | 7.99M | 7.11M | 6.92M | 6.70M | 3.96M | 4.80M | 6.92M | 6.01M | 5.94M | 3.34M | 3.31M | 4.84M |
| Interest Income | 153.00K | 195.00K | 20.00K | 593.00K | 1.10M | 320.00K | 1.72M | 878.00K | 91.00K | 149.00K | 30.00K | 40.00K | 29.00K | 11.00K | 63.00K | 318.00K | 192.00K | 197.00K | 53.00K | 112.00K | 271.00K |
| Interest Expense | 20.00K | 25.00K | 516.00K | 42.00K | 39.00K | 911.00K | 0.00 | 0.00 | 0.00 | 0.00 | 1.00K | 1.00K | 2.00K | 12.00K | 62.00K | 1.00K | 0.00 | 250.00K | 250.00K | 0.00 | 0.00 |
| Depreciation & Amortization | 267.00K | 324.00K | 380.00K | 412.00K | 384.00K | 232.00K | 169.00K | 92.00K | 125.00K | 112.00K | 123.00K | 150.00K | 154.00K | 157.00K | 197.00K | 181.00K | 200.00K | 77.00K | 81.00K | 320.00K | 388.00K |
| EBITDA | -6.37M | -10.71M | -13.00M | -13.40M | -17.70M | -21.00M | -19.72M | -13.63M | -10.27M | -7.86M | -6.94M | -6.69M | -6.48M | -6.05M | -4.41M | -6.39M | -5.78M | -6.37M | -3.01M | -2.98M | -4.43M |
| EBITDA Ratio | -1,201.89% | -2,656.58% | -4,898.83% | -222.65% | -36,116.33% | -46,102.33% | -42,863.04% | -47,006.90% | -34,230.00% | -35,036.36% | -40,794.12% | -16,735.00% | -22,355.17% | -12,125.81% | -4,781.72% | -23,662.96% | -11,371.43% | -62,900.00% | -100,400.00% | -503,500.00% | -21,600.00% |
| Operating Income | -7.12M | -11.23M | -12.91M | -14.41M | -18.28M | -20.38M | -19.89M | -13.72M | -10.39M | -7.97M | -7.09M | -6.88M | -6.67M | -6.22M | -4.67M | -6.89M | -5.96M | -6.83M | -3.34M | -1.25M | -5.15M |
| Operating Income Ratio | -1,342.45% | -2,786.10% | -5,024.90% | -237.58% | -37,310.20% | -47,386.05% | -43,232.61% | -47,324.14% | -34,646.67% | -36,222.73% | -41,694.12% | -17,210.00% | -22,986.21% | -20,058.06% | -5,019.35% | -25,514.81% | -12,171.43% | -75,877.78% | -111,200.00% | -125,300.00% | -27,115.79% |
| Total Other Income/Expenses | 458.00K | 170.00K | -496.00K | 551.00K | 1.06M | -591.00K | 1.72M | 878.00K | 91.00K | 149.00K | 29.00K | 39.00K | 27.00K | -1.00K | 1.00K | 317.00K | 192.00K | -53.00K | -197.00K | 112.00K | 271.00K |
| Income Before Tax | -6.66M | -11.06M | -13.41M | -13.86M | -17.18M | -20.97M | -18.17M | -12.85M | -10.30M | -7.82M | -7.06M | -6.85M | -6.64M | -6.22M | -4.67M | -6.57M | -5.77M | -6.88M | -3.53M | -1.14M | -4.88M |
| Income Before Tax Ratio | -1,256.04% | -2,743.92% | -5,217.90% | -228.49% | -35,059.18% | -48,760.47% | -39,489.13% | -44,296.55% | -34,343.33% | -35,545.45% | -41,523.53% | -17,112.50% | -22,893.10% | -20,061.29% | -5,018.28% | -24,340.74% | -11,779.59% | -76,466.67% | -117,766.67% | -114,100.00% | -25,689.47% |
| Income Tax Expense | -1.25M | -1.37M | -2.06M | -2.45M | -2.89M | -3.35M | -2.59M | -1.49M | -1.40M | -754.00K | -714.00K | -616.00K | -491.00K | -369.00K | -1.00M | 319.00K | -523.00K | -513.00K | -319.00K | -328.00K | -446.00K |
| Net Income | -5.41M | -9.69M | -11.35M | -11.41M | -14.29M | -17.62M | -15.57M | -11.35M | -8.91M | -7.07M | -6.35M | -6.23M | -6.15M | -5.85M | -3.67M | -6.57M | -5.25M | -6.37M | -3.21M | -813.00K | -4.44M |
| Net Income Ratio | -1,020.38% | -2,404.22% | -4,415.18% | -188.16% | -29,167.35% | -40,965.12% | -33,854.35% | -39,151.72% | -29,686.67% | -32,118.18% | -37,323.53% | -15,572.50% | -21,200.00% | -18,870.97% | -3,943.01% | -24,340.74% | -10,712.24% | -70,766.67% | -107,133.33% | -81,300.00% | -23,342.11% |
| EPS | -0.09 | -0.17 | -0.29 | -0.35 | -0.44 | -0.54 | -0.48 | -0.42 | -0.48 | -0.48 | -0.83 | -0.88 | -1.10 | -1.56 | -2.07 | -3.85 | -4.30 | -7.65 | -2.99 | -0.76 | -4.13 |
| EPS Diluted | -0.09 | -0.17 | -0.29 | -0.35 | -0.44 | -0.54 | -0.48 | -0.42 | -0.48 | -0.48 | -0.83 | -0.88 | -1.10 | -1.56 | -2.07 | -3.85 | -4.30 | -7.65 | -2.99 | -0.76 | -4.13 |
| Weighted Avg Shares Out | 57.13M | 56.98M | 39.13M | 32.67M | 32.50M | 32.50M | 32.50M | 26.80M | 18.37M | 14.63M | 7.69M | 7.12M | 5.58M | 3.76M | 1.77M | 1.71M | 1.22M | 832.49K | 1.07M | 1.07M | 1.07M |
| Weighted Avg Shares Out (Dil) | 57.13M | 56.98M | 39.13M | 32.67M | 32.67M | 32.50M | 32.50M | 26.80M | 18.37M | 14.63M | 7.69M | 7.12M | 5.58M | 3.76M | 1.77M | 1.71M | 1.22M | 832.49K | 1.07M | 1.07M | 1.07M |
ReNeuron set to delist after it calls time on equity fundraising effort
ReNeuron Group PLC (AIM:RENE, OTC:RNUGF) said it would delist from AIM after it called time on City fundraising efforts to focus on the ongoing administration process. In an update, the company said it was not in the best interests of existing...
ReNeuron says funding talks ongoing
ReNeuron Group PLC (AIM:RENE, OTC:RNUGF) said it is seeking potential new investors to enable the company to trade as a going concern following an exit from administration. However, there is a discrepancy between the amount it can pay existing creditors...
ReNeuron may have a future as a listed company, investors and creditors told
ReNeuron Group PLC (AIM:RENE, OTC:RNUGF), the stem cell group placed into administration in March, said it is exploring an equity fundraiser to recapitalise the business. In an update, it was stressed that this was just one potential option being mulled alongside...
ReNeuron to showcase drug delivery platform at Cell2023
ReNeuron is to present in vivo data exemplifying the cellular and tissue targeting capabilities and highlighting the significant advantages of its CustomEX drug delivery platform at Cell 2023 in London. Data to be presented shows the significant improvement in targeting and...
ReNeuron highlights exosome platform R&D progress
ReNeuron said it had taken an important step forward with plans to differentiate its exosome platform by generating in vivo data highlighting its distinct organ and cellular targeting capabilities. Iain Ross, executive chairman, said: "On the basis of this data the...
Source: https://incomestatements.info
Category: Stock Reports